Our Institutions
St. John's Medical College
St. John's College of Nursing
St. John's Allied Health Science
St. John's Medical College Hospital
St. John's Research Institute
SJMCH @Brigade Meadows
St John’s Geriatric Centre
Useful Links
Projects
A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer
G R Blumenschein Jr 1 , F Kabbinavar 2 , H Menon 3 , T S K Mok 4 , J Stephenson 5 , J T Beck 6 , K Lakshmaiah 7 , K Reckamp 8 , Y-J Hei 9 , K Kracht 10 , Y-N Sun 11 , R Sikorski 9 , L Schwartzberg 12 ; Motesanib NSCLC Phase II Study Investigators Abstract
Background: This phase II study estimated the difference in objective response rate (ORR) among patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) receiving paclitaxel-carboplatin (CP) plus motesanib or bevacizumab.
